Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced its second-quarter 2026 financial results, revealing a 53% year-over-year drop in operating expenses to $2.29 million and a 47% decrease in general and administrative expenses to $1.76 million. The company’s cash position improved markedly, with cash, cash equivalents, and digital assets totaling approximately $9.5 million as of June 30, compared to $4.1 million at the end of 2025. This liquidity is projected to fund operations at least through October 2027, based on the first-half 2026 burn rate, providing a robust runway for upcoming clinical activities.
The most significant development came after the quarter’s end, when the U.S. Food and Drug Administration (FDA) approved Quantum’s Investigational New Drug (IND) application for Lucid-MS. This clearance allows the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis. Lucid-MS is a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The advancement into Phase 2 marks a critical milestone for Quantum’s lead drug candidate, which is being developed through its wholly owned subsidiary, Lucid Psycheceuticals Inc.
“The FDA’s approval of our IND for Lucid-MS is a pivotal step forward in our mission to address challenging neurodegenerative diseases,” said a company spokesperson. “With our reduced cost structure and extended cash runway, we are well-positioned to execute this Phase 2 trial and potentially bring a new therapeutic option to patients with progressive MS.”
In addition to its MS program, Quantum holds a 19.84% ownership stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets the OTC version of UNBUZZD™. The agreement includes royalty payments of 7% on sales of unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains all rights to develop similar products for pharmaceutical and medical uses, providing potential future revenue streams.
The company’s focus remains on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. With the Phase 2 trial on the horizon, Quantum is poised to generate significant clinical data that could shape the future of MS treatment. The full press release is available at https://nnw.fm/dlAAe.
Investors interested in more details can access the company’s newsroom at https://ibn.fm/QNTM for ongoing updates.
